Damora Therapeutics
DMRA
22 hedge funds and large institutions have $10.2M invested in Damora Therapeutics in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
1.36% less ownership
Funds ownership: 36.08% → 34.71% (-1.4%)
15% less funds holding
Funds holding: 26 → 22 (-4)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
41% less capital invested
Capital invested by funds: $17.3M → $10.2M (-$7.11M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$66.4K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.88K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.67K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$5.06K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$175K |
| 2 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$114K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$79K |
| 4 |
Two Sigma Advisers
New York
|
-$48.8K |
| 5 |
Two Sigma Investments
New York
|
-$48.3K |
DMRA Hedge Fund Activity: Q4 2022 in Review
22 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q4 2022, worth a combined $10.2M — down 41% from $17.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DMRA and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Federated Hermes, adding an estimated $66.4K. The largest seller was MAI Capital Management, cutting an estimated $175K.
- 22 institutional investors held Damora Therapeutics (DMRA) as of Q4 2022, down from 26 in Q3 2022.
- Funds reported $10.2M of Damora Therapeutics stock for Q4 2022, down 41% quarter-over-quarter.
- 1 fund opened new Damora Therapeutics positions in Q4 2022 and 5 closed out, a net change of -4 holders.
- The largest Damora Therapeutics buyer in Q4 2022 was Federated Hermes, an estimated $66.4K added.
- The largest Damora Therapeutics seller in Q4 2022 was MAI Capital Management, an estimated $175K sold.
Based on aggregated 13F filings for Q4 2022.